NCT02955693View on ClinicalTrials.gov

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions

Psoriasis

Interventions

DRUG

LAS41008 120 mg / Fumaderm® 120 mg

Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period

Trial Locations (1)

HA1 3UJ

Almirall Investigational Site #1, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Almirall, S.A.

INDUSTRY